Breen Ronan A M, Miller R F, Gorsuch T, Smith C J, Ainsworth J, Ballinger J, Swaden L, Cropley I, Johnson M A, Lipman M C I
Department of HIV Medicine, Royal Free Hospital, and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, London, United Kingdom.
J Infect Dis. 2006 May 15;193(10):1437-40. doi: 10.1086/503437. Epub 2006 Apr 4.
We compared 156 human immunodeficiency virus (HIV)-infected patients who had tuberculosis with control populations of similar size. Of 111 patients with HIV infection and tuberculosis who received highly active antiretroviral therapy (HAART) and therapy for tuberculosis concurrently, 92 (83%) achieved or maintained virus loads of <50 copies/mL, and 99 (89%) achieved or maintained a >or=2 log10 reduction in virus load after 6 months. Virological response and changes in CD4 cell count were equivalent to those in 111 matched HIV-infected subjects without tuberculosis starting HAART. Tuberculosis recurrence rates were similar to those found in an HIV-uninfected population of 156 subjects (3% and 1%, respectively). Treatment for HIV and tuberculosis does not compromise outcomes for either disease.
我们将156例合并肺结核的人类免疫缺陷病毒（HIV）感染者与规模相似的对照人群进行了比较。在111例同时接受高效抗逆转录病毒治疗（HAART）和抗结核治疗的HIV感染合并肺结核患者中，92例（83%）实现或维持了病毒载量<50拷贝/毫升，99例（89%）在6个月后实现或维持了病毒载量至少降低2个对数10。病毒学反应和CD4细胞计数的变化与111例开始接受HAART的匹配的未合并肺结核的HIV感染受试者相当。结核病复发率与156名未感染HIV的受试者群体中的复发率相似（分别为3%和1%）。HIV和结核病的治疗不会影响任何一种疾病的治疗结果。
